APC Anti-GABA B Receptor 1 antibody [EPR22954-47],Abcam,AB318421

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

Antibody Labelling, Target Binding Affinity, IHC-P

Conjugate

APC

Platform ID

BAB520750593

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAPC Anti-GABA B Receptor 1 antibody [EPR22954-47]
Cat. No.AB318421
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ConjugationAPC
ApplicationAntibody Labelling, Target Binding Affinity, IHC-P
ClonalityMonoclonal
Clone NumberEPR22954-47
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2 (PubMed : 15617512, PubMed : 18165688, PubMed : 22660477, PubMed : 24305054, PubMed : 36103875, PubMed : 9872316, PubMed : 9872744). Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins (PubMed : 18165688). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase (PubMed : 10075644, PubMed : 10773016, PubMed : 10906333, PubMed : 24305054, PubMed : 9872744). Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis (PubMed : 10075644). Calcium is required for high affinity binding to GABA (By similarity). Plays a critical role in the fine-tuning of inhibitory synaptic transmission (PubMed : 9844003). Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials (PubMed : 10075644, PubMed : 22660477, PubMed : 9844003, PubMed : 9872316, PubMed : 9872744). Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception (Probable). Activated by (-)-baclofen, cgp27492 and blocked by phaclofen (PubMed : 24305054, PubMed : 9844003, PubMed : 9872316).. Isoform 1E may regulate the formation of functional GABBR1/GABBR2 heterodimers by competing for GABBR2 binding. This could explain the observation that certain small molecule ligands exhibit differential affinity for central versus peripheral sites. See full target information GABBR1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.